Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Umbralisib with ibrutinib in patients with R/R CLL or MCL

Matthew Davids • 11 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Ibrutinib Umbralisib

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, updates us on long-term results of a Phase Ib study investigating ibrutinib with umbralisib, a PI3Kdelta inhibitor, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Davids

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals